Article information
Abstract
Time is a crucial dimension in most chronic diseases, especially in inflammatory rheumatic disease, which it affects in many ways. Early treatment in rheumatoid arthritis (RA) is an essential issue, as joint damage occurs within the first weeks or months of the disease process and inflammatory activity maintained over time is responsible for all of the consequences of the disease. The introduction of new drugs with faster and more effective action, such as tumor necrosis factor (TNF) inhibitors, has represented a major shift in the strategy of RA treatment, allowing the clinician to aim for remission and prevention of structural damage as realizable goals.
Keywords:
Rheumatoid artritis
Treatment
Early response
AntiTNF
PEGilation
Resumen
El tiempo es una dimensión de importancia capital en la mayoría de las enfermedades crónicas y, especialmente, en las enfermedades reumáticas inflamatorias, donde influye en muchos aspectos. El tratamiento precoz de la artritis reumatoide es esencial, debido a que el proceso destructivo articular comienza muy pronto, en las primeras semanas o meses, y la actividad inflamatoria mantenida en el tiempo es responsable de todas las consecuencias de la enfermedad. La introducción de fármacos nuevos con una acción más rápida y eficaz, como los fármacos biológicos anti-TNF, ha supuesto un cambio radical en la estrategia de tratamiento de la artritis reumatoide, permitiendo, incluso, que la inducción de la remisión y la detención del proceso destructivo articular sean unos objetivos posibles.
Palabras clave:
Artritis reumatoide
Tratamiento
Respuesta precoz
Anti-TNF Certolizumab pegol
Full text is only aviable in PDF
References
[1.]
L. Carmona, V. Villaverde, C. Hernández-García, J. Ballina, R. Gabriel, A. Laffon, et al.
The prevalence of rheumatoid arthritis in the general population of Spain.
Rheumatology (Oxford), 41 (2002), pp. 88-95
[2.]
S.E. Gabriel, C.S. Crowson, W.M. O’Fallon.
The epidemiology of rheumatoid arthritis in Rochester. Minnesota, 1955–1985.
Arthritis Rheum, 42 (1999), pp. 415-420
[3.]
M.J. Plant, P.W. Jones, J. Saklatvala, W.E. Ollier, P.T. Dawes.
Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study.
J Rheumatol, 25 (1998), pp. 417-426
[4.]
Y.S. Sherrer, D.A. Bloch, D.M. Mitchell, D.Y. Young, J.F. Fries.
The development of disability in rheumatoid arthritis.
Arthritis Rheum, 29 (1986), pp. 494-500
[5.]
T. Sokka, H. Makinen.
Drug management of early rheumatoid arthritis-2008.
Best Pract Res Clin Rheumatol, 23 (2009), pp. 93-102
[6.]
B. Combe, R. Landewe, C. Lukas, H.D. Bolosiu, F. Breedveld, M. Dougados, et al.
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
Ann Rheum Dis, 66 (2007), pp. 34-45
[7.]
B. Combe.
Early rheumatoid arthritis: strategies for prevention and management.
Best Pract Res Clin Rheumatol, 21 (2007), pp. 27-42
[8.]
S. Hayer, K. Redlich, A. Korb, S. Hermann, J. Smolen, G. Schett.
Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis.
Arthritis Rheum, 56 (2007), pp. 79-88
[9.]
M. Ostergaard, B. Ejbjerg, M. Szkudlarek.
Imaging in early rheumatoid arthritis: roles of magnetic resonance imaging, ultrasonography, conventional radiography and computed tomography.
Best Pract Res Clin Rheumatol, 19 (2005), pp. 91-116
[10.]
J.C. Buckland-Wright, G.S. Clarke, I.C. Chikanza, R. Grahame.
Quantitative microfocal radiography detects changes in erosion area in patients with early rheumatoid arthritis treated with myocrisine.
J Rheumatol, 20 (1993), pp. 243-247
[11.]
D.M. Van der Heijde, J.W. Jacobs, J.W. Bijlsma, A.H.M. Heurkens, B-FC. Van, V.M.B. Van-der, et al.
The effectineness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial.
Ann Intern Med, 124 (1996), pp. 699-707
[12.]
E. Tsakonas, A.A. Fitzgerald, M.A. Fitzcharles, A. Cividino, J.C. Thorne, A. S'Seffar, et al.
Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study.
J Rheumatol, 27 (2000), pp. 623-629
[13.]
V.P. Nell, K.P. Machold, G. Eberl, T.A. Stamm, M. Uffmann, J.S. Smolen.
Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.
Rheumatology (Oxford), 43 (2004), pp. 906-914
[14.]
T. Mottonen, P. Hannonen, M. Korpela, M. Nissila, H. Kautiainen, J. Ilonen, et al.
Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
Arthritis Rheum, 46 (2002), pp. 894-898
[15.]
J.J. Cush.
Early arthritis clinics: if you build it will they come?.
J Rheumatol, 32 (2005), pp. 203-207
[16.]
V. Villaverde, A. Balsa.
Factores pronósticos de la artritis reumatoide.
Rev Esp Reumatol, 29 (2002), pp. 10-15
[17.]
J.L. Andreu, L. Silva, J. Sanz, P. Muñoz.
Optimización del tratamiento clásico de la artritis reumatoide.
Reumatol Clin, 2 (2006), pp. 51-58
[18.]
D. Green, H. Marzo-Ortega, D. McGonagle, R.J. Wakefield, S.M. Proudman, P.G. Conaghan, et al.
Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope.
Arthritis Rheum, 42 (1999), pp. 2184-2188
[19.]
L.D. Lard, H. Visser, I. Speyer, H-BIE. van-der, A.H. Zwinderman, F.C. Breedveld, et al.
Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies.
Am J Med, 111 (2001), pp. 446-451
[20.]
J.J. Anderson, G. Wells, A.C. Verhoeven, D.T. Felson.
Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.
Arthritis Rheum, 43 (2000), pp. 22-29
[21.]
A. Finckh, M.H. Liang, C.M. van Herckenrode, P. de Pablo.
Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis.
Arthritis Rheum, 55 (2006), pp. 864-872
[22.]
P. Emery, F.C. Breedveld, M. Dougados, J.R. Kalden, M.H. Schiff, J.S. Smolen.
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide.
Ann Rheum Dis, 61 (2002), pp. 290-297
[23.]
A. Martínez, G.E. Batlle, E. Pascual.
Curso y evolución de la artritis reumatoide. Factores pronósticos.
Semin Fund Esp Reumatol, 1 (2000), pp. 65-72
[24.]
V. Villaverde, A. Balsa, E. Martín-Mola.
Estrategias para un diagnóstico y tratamiento precoz de la artritis reumatoide. Implantación de consultas de artritis de reciente comienzo.
Semin Fund Esp Reumatol, 1 (2000), pp. 3-9
[25.]
K.P. Machold, G. Eberl, B.F. Leeb, V. Nell, B. Windisch, J.S. Smolen.
Early arthritis therapy: rationale and current approach.
J Rheumatol Suppl, 53 (1998), pp. 13-19
[26.]
J.S. Smolen, D. Aletaha.
Developments in the clinical understanding of rheumatoid arthritis.
Arthritis Res Ther, 11 (2009), pp. 204
[27.]
D.L. Scott, C. Smith, G. Kingsley.
Joint damage and disability in rheumatoid arthritis: an updated systematic review.
Clin Exp Rheumatol, 21 (2003), pp. S20-S27
[28.]
J.S. Smolen, D.M. Van der Heijde, D. Aletaha, S. Xu, J. Han, D. Baker, et al.
Progression of radiographic joint damage in rheumatoid arthritis: Independence of erosions and joint space narrowing.
Ann Rheum Dis, 68 (2009), pp. 1535-1540
[29.]
R.J. Wakefield, M.J. Green, H. Marzo-Ortega, P.G. Conaghan, W.W. Gibbon, D. McGonagle, et al.
Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease.
Ann Rheum Dis, 63 (2004), pp. 382-385
[30.]
P. Goupille, B. Roulot, S. Akoka, A.M. Avimadje, P. Garaud, L. Naccache, et al.
Magnetic resonance imaging: a valuable method for the detection of synovial inflammation in rheumatoid arthritis.
J Rheumatol, 28 (2001), pp. 35-40
[31.]
R.J. Wakefield, J.E. Freeston, E.M. Hensor, D. Bryer, M.A. Quinn, P. Emery.
Delay in imaging versus clinical response: a rationale for prolonged treatment with antitumor necrosis factor medication in early rheumatoid arthritis.
Arthritis Rheum, 57 (2007), pp. 1564-1567
[32.]
T. Pincus.
Rheumatology function tests: quantitative physical measures to monitor morbidity and predict mortality in patients with rheumatic diseases.
Clin Exp Rheumatol, 23 (2005), pp. S85-S89
[33.]
B. Combe, A. Cantagrel, P. Goupille, M.C. Bozonnat, J. Sibilia, J.F. Eliaou, et al.
Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis.
J Rheumatol, 30 (2003), pp. 2344-2349
[34.]
D. Aletaha, J. Smolen, M.M. Ward.
Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components.
Arthritis Rheum, 54 (2006), pp. 2784-2792
[35.]
D. Aletaha, V. Strand, J.S. Smolen, M.M. Ward.
Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results.
Ann Rheum Dis, 67 (2008), pp. 238-243
[37.]
R.I. del, K. Williams, M.P. Stern, G.L. Freeman, A. Escalante.
High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.
Arthritis Rheum, 44 (2001), pp. 2737-2745
[38.]
P.J. Nicola, H. Maradit-Kremers, V.L. Roger, S.J. Jacobsen, C.S. Crowson, K.V. Ballman, et al.
The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years.
Arthritis Rheum, 52 (2005), pp. 412-420
[39.]
N.J. Goodson, N.J. Wiles, M. Lunt, E.M. Barrett, A.J. Silman, D.P. Symmons.
Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients.
Arthritis Rheum, 46 (2002), pp. 2010-2019
[40.]
J.D. García Díaz, G.A. López de, M.I. Díez-Pérez de la Vacas, Q.E. Cuende, A.A. Sánchez.
Determinants of carotid subclinical atherosclerosis in patients with rheumatoid arthritis. A case-control study.
Med Clin (Barc), 130 (2008), pp. 210-212
[41.]
M.A. González-Gay, C. González-Juanatey, J. Martín.
Inflammation and endothelial dysfunction in rheumatoid arthritis.
Clin Exp Rheumatol, 24 (2006), pp. 115-117
[42.]
P.F. Del, B. Lagana, S. Lai, I. Nofroni, F. Tinti, M. Vitale, et al.
Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intimamedia thickness in patients with active rheumatoid arthritis.
Rheumatology (Oxford), 46 (2007), pp. 1111-1115
[43.]
E. Baecklund, A. Iliadou, J. Askling, A. Ekbom, C. Backlin, F. Granath, et al.
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.
Arthritis Rheum, 54 (2006), pp. 692-701
[44.]
T. Pincus, L.F. Callahan, W.G. Sale, A.L. Brooks, L.E. Payne, W.K. Vaughn.
Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years.
Arthritis Rheum, 27 (1984), pp. 864-872
[45.]
G. Wells, M. Boers, P. Tugwell.
Low disease activity state in rheumatoid arthritis: concepts and derivation of minimal disease activity.
Clinical Experimental Rheumatology, 24 (2006), pp. S9
[46.]
W. Kievit, J. Fransen, A.J. Oerlemans, H.H. Kuper, M.A. Van der Laar, D.J. De Rooij, et al.
The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice.
Ann Rheum Dis, 66 (2007), pp. 1473-1478
[47.]
F.C. Breedveld, M.H. Weisman, A.F. Kavanaugh, S.B. Cohen, K. Pavelka, V.R. van, et al.
The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Arthritis Rheum., 54 (2006), pp. 26-37
[48.]
P. Emery, F.C. Breedveld, S. Hall, P. Durez, D.J. Chang, D. Robertson, et al.
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.
Lancet, 372 (2008), pp. 375-382
[49.]
S.M. Van der Kooij, J.K. De Vries-Bouwstra, Y.P. Goekoop-Ruiterman, Z.D. Van, P.J. Kerstens, A.H. Gerards, et al.
Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.
Ann Rheum Dis, 66 (2007), pp. 1356-1362
[50.]
D. Aletaha, J. Funovits, E.C. Keystone, J.S. Smolen.
Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients.
Arthritis Rheum, 56 (2007), pp. 3226-3235
[51.]
D. Aletaha, J. Funovits, F.C. Breedveld, J. Sharp, O. Segurado, J.S. Smolen.
Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment.
Arthritis Rheum, 60 (2009), pp. 1242-1249
[52.]
J.S. Smolen, C. Han, D.M. van der Heijde, P. Emery, J.M. Bathon, E. Keystone, et al.
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade.
Ann Rheum Dis, 68 (2009), pp. 823-827
[53.]
V. Bejarano, M. Quinn, P.G. Conaghan, R. Reece, A.M. Keenan, D. Walker, et al.
Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis.
Arthritis Rheum, 59 (2008), pp. 1467-1474
[54.]
K. Puolakka, H. Kautiainen, T. Mottonen, P. Hannonen, M. Korpela, M. Hakala, et al.
Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
Arthritis Rheum, 52 (2005), pp. 36-41
[55.]
V. Rantalaiho, M. Korpela, P. Hannonen, H. Kautiainen, S. Jarvenpaa, M. Leirisalo-Repo, et al.
The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Arthritis Rheum, 60 (2009), pp. 1222-1231
[56.]
R. Luqmani, S. Hennell, C. Estrach, F. Birrell, A. Bosworth, G. Davenport, et al.
British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Rheumatoid Arthritis (The first 2 years).
Rheumatology (Oxford), 48 (2009), pp. 436-439
[57.]
K.G. Saag, G.G. Teng, N.M. Patkar, J. Anuntiyo, C. Finney, J.R. Curtis, et al.
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
Arthritis Rheum, 59 (2008), pp. 762-784
[58.]
S. Cohen, G.W. Cannon, M. Schiff, A. Weaver, R. Fox, N. Olsen, et al.
Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Arthritis Rheum, 44 (2001), pp. 1984-1992
[59.]
M.A. Siddiqui.
The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
Curr Opin Rheumatol, 19 (2007), pp. 308-313
[60.]
E.W. St Clair, D.M. van der Heijde, J.S. Smolen, R.N. Maini, J.M. Bathon, P. Emery, et al.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
Arthritis Rheum, 50 (2004), pp. 3432-3443
[61.]
J.A. Bathon, R.W. Martin, R.M. Fleischmann, J.R. Tesser, M.H. Schiff, E.C. Keystone, et al.
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.
N Engl J Med, 343 (2000), pp. 1586-1593
[62.]
E. Keystone, D. Heijde, D. Mason, R. Landewe, R.V. Vollenhoven, B. Combe, et al.
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallelgroup study.
Arthritis Rheum, 58 (2008), pp. 3319-3329
[63.]
Y.P. Goekoop-Ruiterman, J.K. De Vries-Bouwstra, C.F. Allaart, Z.D. Van, P.J. Kerstens, J.M. Hazes, et al.
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Arthritis Rheum, 52 (2005), pp. 3381-3390
[64.]
Y.P. Goekoop-Ruiterman, J.K. de Vries-Bouwstra, C.F. Allaart, P.J. Kerstens, B.A. Grillet, M.H. de Jager, et al.
Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial).
Ann Rheum Dis, 66 (2007), pp. 1227-1232
[65.]
D.M. Van der Heijde, M.E. Weinblatt, R. Landewe, N. Goel, A.F. Wells, R. Fleischmann.
Inhibition of progression of structural damage by week 16 with certolizumab pegol: results from the RAPID trials.
Arthritis and Rheumatism, 58 (2008), pp. 51
[66.]
L.H. Van Tuyl, A.M. Plass, W.F. Lems, A.E. Voskuyl, B.A. Dijkmans, M. Boers.
Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis?.
Ann Rheum Dis, 66 (2007), pp. 974-976
Copyright © 2010. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
